SIGLEC1 and cancer: Recently, in a meta-analysis, Kong et al. [29] found that high expression of CD169 in the regional lymph node is associated with favorable survival outcomes in patients with malignant tumors and that CD169 may be a new, effective prognostic marker for malignancies.